Replimune Free Cash Flow from 2010 to 2024

REPL Stock  USD 12.64  0.00  0.00%   
Replimune Free Cash Flow yearly trend continues to be quite stable with very little volatility. Free Cash Flow may rise above about -181.6 M this year. Free Cash Flow is the amount of cash Replimune Group generates after accounting for cash outflows to support operations and maintain its capital assets. View All Fundamentals
 
Free Cash Flow  
First Reported
2017-06-30
Previous Quarter
-50.8 M
Current Value
-40.7 M
Quarterly Volatility
15.4 M
 
Covid
Check Replimune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Replimune's main balance sheet or income statement drivers, such as Interest Income of 935.8 K, Depreciation And Amortization of 2 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.44. Replimune financial statements analysis is a perfect complement when working with Replimune Valuation or Volatility modules.
  
Check out the analysis of Replimune Correlation against competitors.

Latest Replimune's Free Cash Flow Growth Pattern

Below is the plot of the Free Cash Flow of Replimune Group over the last few years. It is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets. Replimune's Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow10 Years Trend
Slightly volatile
   Free Cash Flow   
       Timeline  

Replimune Free Cash Flow Regression Statistics

Arithmetic Mean(54,249,570)
Coefficient Of Variation(120.14)
Mean Deviation52,388,417
Median(16,150,000)
Standard Deviation65,174,169
Sample Variance4247.7T
Range183.8M
R-Value(0.87)
Mean Square Error1100.2T
R-Squared0.76
Significance0.000023
Slope(12,700,467)
Total Sum of Squares59467.4T

Replimune Free Cash Flow History

2024-181.6 M
2023-191.1 M
2022-130.3 M
2021-84.5 M
2020-63.8 M
2019-67.1 M
2018-28 M

Other Fundumenentals of Replimune Group

Replimune Free Cash Flow component correlations

About Replimune Financial Statements

Replimune investors utilize fundamental indicators, such as Free Cash Flow, to predict how Replimune Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Free Cash Flow-191.1 M-181.6 M
Free Cash Flow Yield(0.37)(0.35)
Free Cash Flow Per Share(2.87)(3.01)
EV To Free Cash Flow(2.70)(2.83)
Price To Free Cash Flows Ratio(2.69)(2.83)
Free Cash Flow Operating Cash Flow Ratio 1.03  1.16 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:
Check out the analysis of Replimune Correlation against competitors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Return On Assets
(0.27)
Return On Equity
(0.50)
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.